We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+44.88%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$346M
AUM Growth
–
Cap. Flow
+$310M
Cap. Flow %
89.56%
Top 10 Hldgs %
37.82%
Holding
69
New
69
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$18.9M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$16.3M
3
ZBH icon
Zimmer Biomet
ZBH
+$13.5M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$12.7M
5
BSX icon
Boston Scientific
BSX
+$11.5M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 91.87%
2 Industrials 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NEPH icon
51
Nephros
NEPH
$46.4M
$1.99M 0.57%
+199,724
New +$1.78M
MNKD icon
52
MannKind Corp
MNKD
$1.23B
$1.84M 0.53%
+1,425,302
New +$1.82M
INSP icon
53
Inspire Medical Systems
INSP
$1.71B
$1.84M 0.53%
+24,750
New +$1.59M
TECX
54
Tectonic Therapeutic
TECX
$623M
$1.81M 0.52%
+7,500
New +$1.45M
MGTX icon
55
MeiraGTx Holdings
MGTX
$1.21B
$1.65M 0.48%
+82,294
New +$1.41M
FTSV
56
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$1.57M 0.45%
+40,000
New +$643K
MYOV
57
DELISTED
Myovant Sciences Ltd.
MYOV
$1.54M 0.45%
+99,413
New +$1M
LAB icon
58
Standard BioTools
LAB
$309M
$1.39M 0.4%
+400,000
New +$1.41M
SPNE
59
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$1.35M 0.39%
+112,440
New +$1.37M
MBIO icon
60
Mustang Bio
MBIO
$4.61M
$1.23M 0.36%
+403
New +$923K
BHVN
61
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.09M 0.31%
+20,000
New +$990K
CDMO
62
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$1.08M 0.31%
+140,523
New +$820K
INFU icon
63
InfuSystem Holdings
INFU
$248M
$1.07M 0.31%
+125,000
New +$920K
XNCR icon
64
Xencor
XNCR
$1.64B
$860K 0.25%
+25,000
New +$913K
ITMR
65
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$604K 0.17%
+46,900
New +$464K
PHAS
66
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$557K 0.16%
+91,091
New +$375K
ACRS icon
67
Aclaris Therapeutics
ACRS
$871M
$425K 0.12%
+225,000
New +$373K
TELA icon
68
TELA Bio
TELA
$35.4M
$324K 0.09%
+25,000
New +$306K
APYX icon
69
Apyx Medical
APYX
$127M
$299K 0.09%
+35,395
New +$256K
1 2
3

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2019 Portfolio in Review

Q4 2019 is the first quarter with a 13F filing on record for Parkman Healthcare Partners, which disclosed 69 positions worth $346M. Its ten largest holdings account for 38% of the portfolio.

Its largest position is Merck: 230,560 shares worth $20M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, followed by Industrials.

  • Parkman Healthcare Partners's largest Q4 2019 buy was Merck: 230,560 shares worth $20M.
  • Parkman Healthcare Partners's ten largest holdings make up 38% of its $346M portfolio in Q4 2019.
  • Parkman Healthcare Partners disclosed 69 positions in Q4 2019, its first 13F filing on record.

Based on Parkman Healthcare Partners's 13F filing for Q4 2019, filed 13 Feb 2020.